Aug 15, 2024
NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT
Jan 26, 2024
Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide
Jan 05, 2024
Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide
Feb 24, 2021
Additional Positive Interim Results from Nanoform's Clinical Study
Feb 12, 2021
Invitation to presentation of Nanoform's year-end report for 2020 on February 26, 2021
Feb 09, 2021
Nanoform and Herantis sign Biologics Proof of Concept Agreement
Jan 22, 2021
Nanoform's Clinical Study Indicates Positive Interim Results
Jan 04, 2021
Nanoform sets a new near-term business target for 2021
Dec 21, 2020
First dosing of nanoformed drug successfully accomplished
Dec 17, 2020
Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules
Dec 02, 2020
Nanoform makes US TV debut in Advancements with Ted Danson (CNBC)
Nov 27, 2020
Nanoform Finland Plc, Interim Report January - September 2020, November 27th, 2020 at 08:00 a.m. Finnish time
Nov 11, 2020
Nanoform to present at Avanza Börsdag on November 18th
Sep 01, 2020
Resolutions of Nanoform Finland Plc's Extraordinary General Meeting and Board of Directors on September 1, 2020
Aug 28, 2020
Nanoform Finland PLC, 2020 Half Year Financial Report, 28 August 2020 At 8:10 Am EEST
Aug 06, 2020
Nanoform convenes EGM to elect Cynthia Schwalm as board member
Apr 09, 2020
Nanoform Appoints Miguel Calado as Chairman of the Board